Amgen Inc. ( AMGN) Q4 2025 Earnings Call February 3, 2026 4:30 PM EST My name is Julianne, and I will be your conference facilitator today for the Amgen Q4 2025 Earnings Conference Call. [Operator ...
Amgen Inc. (AMGN) reported strong Q4 2025 results and provided full-year 2026 guidance that was above Street expectations. The company is managing losses of exclusivity on several large products quite ...
Ahead of this week's Opening Ceremony at the Winter Olympics in Milan, the World Anti-Doping Agency has addressed claims originating from a German tabloid that male skiers could be injecting ...
Sullivan is professor of health economics and policy and former dean of pharmacy at the University of Washington. Hansen is professor of health economics and policy and chair of the Department of ...
For decades, hospitals have given babies a vitamin K injection to protect against bleeding. Now, the shot appears to be facing resistance. By Maggie Astor For most of his 10 years as a neonatologist, ...
The website is targeted at consumers looking to buy drugs without using insurance, meaning that most purchases would not count toward patients' insurance deductibles. US President Donald Trump on ...
Wegovy might be getting more competition soon. During the first half of 2025, Wegovy and Zepbound, two weight loss drugs, ranked among the top 10 best-selling medicines worldwide. And given current ...
Amgen AMGN is off to a strong start in 2025 with its first-quarter earnings as well as sales beating estimates. Particularly, its strong top-line performance caught investor attention. Amgen’s total ...
Amgen's Q4 results beat expectations, shares rise modestly MariTide seen as a paradigm-changing weight-loss drug Amgen's 2026 earnings forecast suggests modest upside, says Citi analyst Feb 3 (Reuters ...
Hosted on MSN
Gene editing breakthrough could end your daily cholesterol pills – here's what it means for you
Your medicine cabinet might look very different in five years. Scribe Therapeutics announced that STX-1150, a one-time CRISPR-based therapy, will enter human trials mid-2026 with the potential to ...
Both ADOS-2 training workshops provide experienced autism professionals with introductory training on the use of the ADOS-2 in clinical settings across ages, developmental levels, and language skills.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results